Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Economics of Prophylaxis and Enduring Neuron Restoration

Blarcamesine won't be a cure [for Alzheimer's], either....

Not discussed in this continuing diatribe on blarcamesine costs and revenues is the fact that its greatest use and impact will be its prophylactic application, prevention of Alzheimer's, and other central nervous system diseases.

There continue to be new, effective, accurate tests for the detection of both Alzheimer's and Parkinson's before any untoward symptoms appear. People at these stages of the diseases, when they are just starting, are still normal; don't even know they have or will get a CNS disease. Treatment with blarcamesine early-on, before neurons and brain regions have been physically and biochemically injured, will be an essential "cure," before the diseases actually appear.

I'm considering how my health insurance company might deal with a test that shows, for sure, that I'm going to start getting Alzheimer's symptoms. Without blarcamesine, I'm doomed to years of mental and physical decline, with hundreds of thousands of dollars of costs, to me and my insurance company. (This actually happened with my father; know the scenario well.) But if blarcamesine were available, would my health insurance company say to me, "Well, we see from your doctor's test that you are going to get and die with Alzheimer's. Get hold of us when you have to be institutionalized; at that time we'll help pay for those blarcamesine costs."

Or, "Your prescription for blarcamesine can be picked up at your pharmacy today. We are glad that with this new blarcamesine drug it will keep you from getting and dying from the Alzheimer's you were destined to get."

Which costs the insurance company more, the straight costs of the drug, alone; or after Alzheimer's sets in the costs of both the drug and all of the consequent health care costs maintaining a patient with full-on Alzheimer's, for any number of years?

Then, this scenario has never been mentioned (except by me, some time ago). There is a distinct possibility that if both Alzheimer's or Parkinson's are prevented with blarcamesine, after a certain treatment period, before any frank symptoms appear, neuron morphology and physiology are both restored to youthful levels. With neurons working as they did when the patient was in her forties or fifties, they may well continue to function normally for the rest of her life. Prophylactic treatments may need to occur for only certain periods of time, say, a year or two, then terminated; whereafter neurons continue to function normally.

Lastly, there is a high possibility that Anavex 3-71 will therapeutically perform far better than blarcamesine, facilitating even better all that I've described. With all of the locked-doors tests Anavex has conducted on tests on age-testing worms (Caenorhabitis elegans) and transgenic murines, lab rodents with human genes for human CNS diseases, the company knows its profound future --- to be publicly revealed at the right times in the future.